Federal Register / Vol. 70, No.
140 / Friday, July 22, 2005 / Notices
a license. The prospective exclusive
license will be royalty-bearing and will
comply with the terms and conditions
of 35 U.S.C. 209 and 37 CFR 404.7. The
prospective exclusive license may be
granted unless, within fifteen (15) days
from the date of this published Notice,
the Department of Veterans Affairs
Office of Research and Development
receives written evidence and argument
which establishes that the grant of the
license would not be consistent with the
requirements of 35 U.S.C. 209 and 37
CFR 404.7.
Approved: July 13, 2005.
Gordon H. Mansfield,
Deputy Secretary, Department of Veterans
Affairs.
[FR Doc. 05–14542 Filed 7–21–05; 8:45 am]
BILLING CODE 8320–01–P
DEPARTMENT OF VETERANS
AFFAIRS
Notice of Intent To Grant an Exclusive
License
AGENCY: Department of Veterans Affairs,
Office of Research and Development.
ACTION: Notice of intent.
SUMMARY: Notice is hereby given that
the Department of Veterans Affairs,
Office of Research and Development,
intends to grant Global Therapy
Monitoring LLC, 6931 Arlington Road,
Bethesda, MD 20814 USA an exclusive
license to practice the following patent
applications: U.S. Provisional Patent
Application Serial No. 60/547,052 filed
February 25, 2004, entitled ‘‘Methods
VerDate jul<14>2003 19:28 Jul 21, 2005 Jkt 205001
42415
for Diagnosing and Treating Bladder
Cancer’’; U.S. Provisional Patent
Application Serial No. 60/532,889 filed
December 30, 2003, entitled
‘‘Macrophage Migration Inhibitory
Factor (MIF) as a Marker for Urological
Inflammatory Disease’’; U.S. Patent
Application Serial No. 10/644,797 filed
on August 21, 2003, and International
Patent Application Serial No. PCT/
US04/05288 filed on February 24, 2004,
entitled ‘‘Serum Macrophage Migration
Inhibitory Factor (MIF) as a Marker for
Prostate Cancer.’’
DATES: Comments must be received
within fifteen (15) days from the date of
this published Notice.
ADDRESSES: Send comments to Saleem J.
Sheredos, Acting Director of Technology
Transfer, Department of Veterans
Affairs; Office of Research and
Development, Attn: 12TT; 103 South
Gay Street, Baltimore, MD 21202.
Telephone: (410) 962–1800 ext 267;
Facsimile: (410) 962–2141; e-mail:
saleem@vard.org.
FOR FURTHER INFORMATION CONTACT:
Copies of the published patent
applications may be obtained from the
U.S. Patent and Trademark Office at
http://www.uspto.gov.
SUPPLEMENTARY INFORMATION: It is in the
public interest to so license these
inventions as Global Therapy
Monitoring LLC submitted a complete
and sufficient application for a license.
The prospective exclusive license will
be royalty-bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR 404.7. The prospective
exclusive license may be granted unless,
PO 00000 Frm 00117 Fmt 4703 Sfmt 4703 E:\FR\FM\22JYN1.SGM
within fifteen (15) days from the date of
this published Notice, the Department
of Veterans Affairs Office of Research
and Development receives written
evidence and argument which
establishes that the grant of the license
would not be consistent with the
requirements of 35 U.S.C. 209 and 37
CFR 404.7.
Approved: July 13, 2005.
Gordon H. Mansfield,
Deputy Secretary of Veterans Affairs.
[FR Doc. 05–14541 Filed 7–21–05; 8:45 am]
BILLING CODE 8320–01–P
DEPARTMENT OF VETERANS
AFFAIRS
VA Fleet Alternative Fuel Vehicle (AFV)
Program Report
AGENCY: Department of Veterans Affairs.
ACTION: Notice.
SUMMARY: In accordance with the Energy
Policy Act of 1992 (EPAct) (42 U.S.C.
13211–13219) as amended by the
Energy Conservation Reauthorization
Act of 1998 (Pub. L. 105–388), the
Department of Veterans Affairs’ annual
alternative fuel reports are available on
the following Department of Veterans
Affairs Web site: http://www.va.gov/afv.
FOR FURTHER INFORMATION CONTACT:
Elaine Jackson, (202) 273–5859.
Approved: July 13, 2005.
Gordon H. Mansfield,
Deputy Secretary of Veterans Affairs.
[FR Doc. 05–14540 Filed 7–21–05; 8:45 am]
BILLING CODE 8320–01–P
22JYN1